Trial Profile
A Double-blind, Randomised, Placebo Controlled, Six-way Crossover Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Influence of Via Respimat® Inhaled BI 1744 CL (Single Doses of 10 μg, 20 μg, 30 μg and 50 μg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2014
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary) ; Moxifloxacin
- Indications Asthma; Bacterial infections; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 22 May 2013 New trial record